Researchers at the University of Leicester and Leicester's Hospitals are evaluating a revolutionary device which detects lung cancer in early stages.
A clinical trial led by University of Leicester respiratory experts into a potentially ground-breaking "breath test" to detect lung cancer is set to get underway at the Glenfield Hospital in Leicester.
It is hoped that the LuCID (Lung Cancer Indicator Detection) programme will lead to a non-invasive method of diagnosing lung cancer in the early stages. The company behind the device, Cambridge-based Owlstone Nanotech Ltd, carried out a health economic analysis and determined that detection of early-stage lung cancer could be increased from the current 14.5% to 25% by 2020, it is estimated this could save 10,000 lives and £250 million (approximately $384,537,500) of National Health Service money. A clinical trial led by University of Leicester respiratory experts into a potentially ground-breaking 'breath test' to detect lung cancer is set to get underway at the Glenfield Hospital in Leicester.
Link to the complete article on MedicalXpress: http://bit.ly/1DxHzXE